ClinicalTrials.gg
CompletedNCT02228460Updated Dec 17, 2019Results posted

Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease

A Phase 2 interventional study of GZ/SAR402671 in Fabry Disease, sponsored by Genzyme, a Sanofi Company. Completed at 8 sites in 5 countries. Open to male participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 49 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Fabry Disease by Sanofi — 1 open to participants now, 3 under way, 2 of them phase 3. Fabry Disease · Sanofi.

Enrollment
13th of 19
11 · median 20
Started
2014
the only one that year
Phase 2
5 of 23
none open now
Registered
15th of 23
by date

Among the 23 studies in Fabry Disease by Sanofi, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2014, is one of 5 in phase 2, and was the 15th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

1 of the 23 studies in Fabry Disease by Sanofi is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 49 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Fabry Disease by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of GZ/SAR402671 in enzyme replacement therapy treatment-naïve adult male participants diagnosed with Fabry disease.

Read the detailed description

The total duration of study per participant was 7 to 8 months for participants who entered a planned extension study and approximately 13 to 14 months for participants who did not enter a planned extension study. A 2-year extension study was planned for eligible participants.

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Venglustat
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant was greater than equal to (>=) 18 years of age and less than (\<) 50 years of age.
  • The participant was male.
  • The participant had provided a signed .
  • The participant had a confirmed diagnosis of Fabry disease as documented by leukocyte α- Galactosidase A (αGAL) activity of \<4 nanomole/hour/milligram (nmol/hr/mg) leukocyte (preferred assay; results from a central laboratory) or plasma αGAL \<1.5 nanomole/hour/milliliter (nmol/hr/mL) (results from a central laboratory).
  • The participant had a plasma globotriaosylsphingosine (lyso-GL3) >=65 nanogram per milliliter (ng/mL).
  • The participant had never been treated with a Fabry disease-specific treatment.
  • If the participant was on renin-angiotensin-aldosterone system (RAAS) blockers and antidepressants, the dose should be stable (i.e., prescribed dose and frequency) for at least the immediate 3 months prior to screening.

Exclusion criteria

Exclusion criteria:

  • The participant had an estimated (eGFR) \<60 mL/min/1.73 m\^2 using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
  • The participant had a median urine protein/creatinine ratio (PCR) >=0.5 gram per gram (g/g) (median of 3 overnight urine collections. Collection of each of the 3 samples must occur between 4 and 7 days of each other, and all samples must be collected within a 15 day period). All 3 samples must be collected regardless of the results and results available prior to Day 1.
  • The participant had undergone a kidney transplant.
  • The participant had either active or a history of organic disease (with the exception of the symptoms related to Fabry disease), including clinically significant cardiovascular, hepatic, pulmonary, hematologic, neurological or renal disease, or other medical condition, serious inter-current illness, or extenuating circumstances that, in the opinion of the Investigator, would preclude participation in the trial.
  • The participant had abnormal liver function (serum total > the , or serum ([ALT] and aspartate aminotransferase [AST] >2.0 times the upper limit of normal).
  • The participant had, according to World Health Organization (WHO) grading a cortical cataract (COR) > one-quarter of the lens circumference (Grade COR-2) or a posterior subcapsular cataract (PSC) >2 millimeter (mm) (Grade PSC-2). Participants with nuclear cataracts were not excluded.
  • The participant was currently receiving potentially cataractogenic medications.
  • The participant had received strong or moderate inducers or inhibitors of Cytochrome P450 3A4 () per Food and Drug Administration (FDA) classification within 14 days prior to enrollment or within 5 times the elimination half-life or PD half-life of the medication, whichever is longer.
  • The participant was scheduled for in-patient hospitalization, including elective surgery, during the study.
  • The participant had a positive result on any of the following tests: surface antigen (HBsAg), anti- virus (anti-HCV) antibodies, anti- 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab). Participants with a positive hepatitis B surface antibody (HBsAb) test with a history of prior hepatitis B immunization were eligible if other criteria met (i.e., negative tests for: HBsAg, hepatitis B core antibody [HBcAb], and hepatitis C virus antibody [HCVAb]).
  • The participant had participated in a study involving an drug within the past 30 days of the start of the trial.
  • The participant was unwilling to comply with the requirements of the protocol.
  • The participant was a sexually active man who was not willing to use 2 forms of including a barrier method during the study until 6 weeks after the last treatment with investigational medicinal product (IMP).
  • The participant had a history or ongoing clinically significant cardiac arrhythmia, defined as either atrial fibrillation, sustained or non-sustained ventricular tachycardia.
  • The participant had any to magnetic resonance imaging (MRI).
  • The participant had one of the following central nervous system exclusion criteria:

    • Acute stroke, within 3 months of the screening visit.
    • History of seizures.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    GZ/SAR402671

    GZ/SAR402671 15 milligram (mg) once daily orally for 26 weeks.

    Drug: GZ/SAR402671

Interventions

  • DrugGZ/SAR402671

    Drug page: Venglustat

    Pharmaceutical form: Capsule; Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26

    Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from Baseline GL-3 score to Week 26 GL-3 score. Any shift category of Baseline score/Week 26 score that was not observed is not reported. Shift to lower score from Baseline to Week 26 indicates less severe condition at Week 26.

    Time frame: Baseline, Week 26

  2. Mean Change From Baseline at Week 26 in Skin GL-3 Score in Superficial Skin Capillary Endothelium

    Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Change from Baseline in GL-3 score was obtained by subtracting Baseline value from post-baseline value at Week 26. A negative change from Baseline indicates less severe condition at Week 26.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in Plasma GL-3 Concentration at Week 26

    Change from Baseline in plasma GL-3 was obtained by subtracting Baseline value from post-baseline value at Week 26. Concentration of GL-3 in plasma was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method.

    Time frame: Baseline, Week 26

  2. Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso-GL-3) Concentration at Week 26

    Change from Baseline in plasma Lyso-GL-3 was obtained by subtracting Baseline value from post-baseline value at Week 26. Concentration of lyso-GL-3 in plasma was determined using a validated LC-MS/MS method.

    Time frame: Baseline, Week 26

  3. Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration at Week 26

    Change from Baseline in plasma GL-1 was obtained by subtracting Baseline value from post-baseline value at Week 26. Concentration of GL-1 in plasma was determined using a validated LC-MS/MS method.

    Time frame: Baseline, Week 26

  4. Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26

    Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from Baseline GL-3 score to Week 26 GL-3 score. Any shift category of Baseline score/Week 26 score that was not observed is not reported. Shift to lower score from Baseline to Week 26 indicates less severe condition at Week 26.

    Time frame: Baseline, Week 26

  5. Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26

    Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from Baseline GL-3 score to Week 26 GL-3 score. Any shift category of Baseline score/Week 26 score that was not observed is not reported. Shift to lower score from Baseline to Week 26 indicates less severe condition at Week 26.

    Time frame: Baseline, Week 26

  6. Change From Baseline at Week 26 in Skin GL-3 Score in Perineurium Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26

    Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from Baseline GL-3 score to Week 26 GL-3 score. Any shift category of Baseline score/Week 26 score that was not observed is not reported. Shift to lower score from Baseline to Week 26 indicates less severe condition at Week 26.

    Time frame: Baseline, Week 26

  7. Change From Baseline in Urine Globotriaosylceramide (GL-3) Concentration at Week 26

    Change from Baseline in urine GL-3 was obtained by subtracting Baseline value from post-baseline value at Week 26. Concentration of GL-3 in urine was determined using a validated LC-MS/MS method.

    Time frame: Baseline, Week 26

  8. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened during on-treatment period (period from the first administration of study drug through the last administration of the study drug plus 30 days or end of study participation for participant, whichever occurs first).

    Time frame: From Baseline up to 212 days

  9. Pharmacokinetics (PK): Maximum Plasma Drug Concentration (Cmax) of GZ/SAR402671

    Maximum plasma concentration observed for study drug was reported.

    Time frame: Day 1 (predose and 1, 2, 4, 8, and 24 hours post-dose); Day 182 (predose and 1, 2, 4, 8, and 24 hours post-dose)

  10. PK: Plasma Trough Concentration (Ctrough) of GZ/SAR402671

    Ctrough was defined as the plasma concentration of study drug observed just before treatment administration during repeated dosing.

    Time frame: Predose on Days 14, 28, 56, 84, 126, and 182

  11. PK: Time to Reach Maximum Plasma Drug Concentration (Tmax) of GZ/SAR402671

    Tmax was defined as time to reach maximum plasma concentration of study drug.

    Time frame: Day 1 (predose and 1, 2, 4, 8, and 24 hours post-dose); Day 182 (predose and 1, 2, 4, 8, and 24 hours post-dose)

  12. PK: Area Under Plasma Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24) of GZ/SAR402671

    Area under the plasma concentration versus time curve of study drug from time 0 to 24 hours (AUC0-24) was calculated using the trapezoidal method over the dosing interval.

    Time frame: Day 1 (predose and 1, 2, 4, 8, and 24 hours post-dose); Day 182 (predose and 1, 2, 4, 8, and 24 hours post-dose)

  13. PK: Terminal Half-life (t1/2z) of GZ/SAR402671

    Plasma t1/2z was the time measured for the plasma concentration of drug to decrease by one half. The t1/2z was estimated based on 24-hour post-dose PK.

    Time frame: Day 1 (predose and 1, 2, 4, 8, and 24 hours post-dose); Day 182 (predose and 1, 2, 4, 8, and 24 hours post-dose)

  14. PK: Apparent Total Body Clearance of GZ/SAR402671 at Steady State (CLss/F)

    Apparent total body clearance at steady state was a quantitative measure of rate of clearance of drug from the blood following oral administration, and is described in terms of volume of fluid clear of drug per time unit (eg, mL/min).

    Time frame: Predose and 1, 2, 4, 8, and 24 hours post-dose on Day 182

  15. PK: Apparent Volume of Distribution of GZ/SAR402671 (Vss/F) at Steady State

    Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of drug.

    Time frame: Predose and 1, 2, 4, 8, and 24 hours post-dose on Day 182

  16. PK: Cumulated Amount of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (Ae0-24)

    Ae0-24 was the cumulated amount of study drug excreted in urine during the time interval of 0 to 24 hours.

    Time frame: 0-24 hours on Day 182

  17. PK: Percentage of Dose of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (fe0-24)

    fe0-24 was the fraction of dose excreted in urine during the time interval of 0 to 24 hours.

    Time frame: 0-24 hours on Day 182

  18. PK: Renal Clearance (CLR) of GZ/SAR402671 From 0 to 24 Hours

    CLR was calculated by dividing the cumulative amount of drug excreted in urine during the dosing interval of 0-24 hours by area under the plasma drug concentration time-curve during the dosing interval of 0-24 hours.

    Time frame: 0-24 hours on Day 182

07

Results

Posted Dec 17, 2019

Participant flow

Participants were enrolled in the study at 8 centers in 5 countries between 11 November 2014 and 06 September 2016. A total of 14 participants were screened in the study.

Participant flow — Overall Study
MilestoneGZ/SAR402671
Started11
Completed9
Not completed2
Withdrew: Adverse event1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26

Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from Baseline GL-3 score to Week 26 GL-3 score. Any shift category of Baseline score/Week 26 score that was not observed is not reported. Shift to lower score from Baseline to Week 26 indicates less severe condition at Week 26.

Time frame:
Baseline, Week 26
Reported as:
Count of participants · Participants
Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26
ParticipantsGZ/SAR402671
Baseline Score: 1 / Week 26 Score: 14
Baseline Score: 1 / Week 26 Score: 21
Baseline Score: 2 / Week 26 Score: 13
Baseline Score: 2 / Week 26 Score: 21
Statistical analysis
  • GZ/SAR402671 · McNemar Test · p = 0.3173 (Threshold for significance at 0.05 level.)
PrimaryMean Change From Baseline at Week 26 in Skin GL-3 Score in Superficial Skin Capillary Endothelium

Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Change from Baseline in GL-3 score was obtained by subtracting Baseline value from post-baseline value at Week 26. A negative change from Baseline indicates less severe condition at Week 26.

Time frame:
Baseline, Week 26
Reported as:
Mean · score on a scale
Mean Change From Baseline at Week 26 in Skin GL-3 Score in Superficial Skin Capillary Endothelium
score on a scaleGZ/SAR402671
Mean Change From Baseline at Week 26 in Skin GL-3 Score in Superficial Skin Capillary Endothelium-0.22 (-0.73 to 0.29)
Statistical analysis
  • GZ/SAR402671 · Wilcoxon signed rank test · p = 0.625 (Threshold for significance at 0.05 level.)
SecondaryChange From Baseline in Plasma GL-3 Concentration at Week 26

Change from Baseline in plasma GL-3 was obtained by subtracting Baseline value from post-baseline value at Week 26. Concentration of GL-3 in plasma was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method.

Time frame:
Baseline, Week 26
Reported as:
Mean · mcg/mL
Change From Baseline in Plasma GL-3 Concentration at Week 26
mcg/mLGZ/SAR402671
Change From Baseline in Plasma GL-3 Concentration at Week 26-3.62 ± 1.07
SecondaryChange From Baseline in Plasma Lyso Globotriaosylceramide (Lyso-GL-3) Concentration at Week 26

Change from Baseline in plasma Lyso-GL-3 was obtained by subtracting Baseline value from post-baseline value at Week 26. Concentration of lyso-GL-3 in plasma was determined using a validated LC-MS/MS method.

Time frame:
Baseline, Week 26
Reported as:
Mean · ng/mL
Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso-GL-3) Concentration at Week 26
ng/mLGZ/SAR402671
Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso-GL-3) Concentration at Week 26-30.99 ± 22.83
SecondaryChange From Baseline in Plasma Glucosylceramide (GL-1) Concentration at Week 26

Change from Baseline in plasma GL-1 was obtained by subtracting Baseline value from post-baseline value at Week 26. Concentration of GL-1 in plasma was determined using a validated LC-MS/MS method.

Time frame:
Baseline, Week 26
Reported as:
Mean · mcg/mL
Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration at Week 26
mcg/mLGZ/SAR402671
Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration at Week 26-3.26 ± 1.43
SecondaryChange From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26

Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from Baseline GL-3 score to Week 26 GL-3 score. Any shift category of Baseline score/Week 26 score that was not observed is not reported. Shift to lower score from Baseline to Week 26 indicates less severe condition at Week 26.

Time frame:
Baseline, Week 26
Reported as:
Count of participants · Participants
Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26
ParticipantsGZ/SAR402671
Baseline Score: 1 / Week 26 Score: 11
Baseline Score: 2 / Week 26 Score: 12
Baseline Score: 2 / Week 26 Score: 26
SecondaryChange From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26

Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from Baseline GL-3 score to Week 26 GL-3 score. Any shift category of Baseline score/Week 26 score that was not observed is not reported. Shift to lower score from Baseline to Week 26 indicates less severe condition at Week 26.

Time frame:
Baseline, Week 26
Reported as:
Count of participants · Participants
Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26
ParticipantsGZ/SAR402671
Baseline Score: 1.5 / Week 26 Score: 1.52
Baseline Score: 2 / Week 26 Score: 27
SecondaryChange From Baseline at Week 26 in Skin GL-3 Score in Perineurium Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26

Skin biopsies taken at Baseline and Week 26 were analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Three independent pathologists evaluated each biopsy using an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe), where higher score indicated more severe condition. A single score per participant per time point was derived by taking the score rated by a majority of the pathologists; if a majority score could not be derived, the median score was used. Data were summarized and reported in terms of number of participants with shift from Baseline GL-3 score to Week 26 GL-3 score. Any shift category of Baseline score/Week 26 score that was not observed is not reported. Shift to lower score from Baseline to Week 26 indicates less severe condition at Week 26.

Time frame:
Baseline, Week 26
Reported as:
Count of participants · Participants
Change From Baseline at Week 26 in Skin GL-3 Score in Perineurium Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26
ParticipantsGZ/SAR402671
Baseline Score: 1 / Week 26 Score: 21
Baseline Score: 2 / Week 26 Score: 28
SecondaryChange From Baseline in Urine Globotriaosylceramide (GL-3) Concentration at Week 26

Change from Baseline in urine GL-3 was obtained by subtracting Baseline value from post-baseline value at Week 26. Concentration of GL-3 in urine was determined using a validated LC-MS/MS method.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/mmol Cr
Change From Baseline in Urine Globotriaosylceramide (GL-3) Concentration at Week 26
mg/mmol CrGZ/SAR402671
Change From Baseline in Urine Globotriaosylceramide (GL-3) Concentration at Week 26-0.25 ± 0.19
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened during on-treatment period (period from the first administration of study drug through the last administration of the study drug plus 30 days or end of study participation for participant, whichever occurs first).

Time frame:
From Baseline up to 212 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsGZ/SAR402671
Number of Participants With Treatment Emergent Adverse Events (TEAEs)9
SecondaryPharmacokinetics (PK): Maximum Plasma Drug Concentration (Cmax) of GZ/SAR402671

Maximum plasma concentration observed for study drug was reported.

Time frame:
Day 1 (predose and 1, 2, 4, 8, and 24 hours post-dose); Day 182 (predose and 1, 2, 4, 8, and 24 hours post-dose)
Reported as:
Mean · ng/mL
Pharmacokinetics (PK): Maximum Plasma Drug Concentration (Cmax) of GZ/SAR402671
ng/mLGZ/SAR402671
Day 124.7 ± 5.89
Day 182192.0 ± 96.4
SecondaryPK: Plasma Trough Concentration (Ctrough) of GZ/SAR402671

Ctrough was defined as the plasma concentration of study drug observed just before treatment administration during repeated dosing.

Time frame:
Predose on Days 14, 28, 56, 84, 126, and 182
Reported as:
Mean · ng/mL
PK: Plasma Trough Concentration (Ctrough) of GZ/SAR402671
ng/mLGZ/SAR402671
Day 14152.0 ± 68.9
Day 28165.0 ± 66.1
Day 56182.0 ± 90.3
Day 84164.0 ± 124.0
Day 126175.0 ± 94.7
Day 182164.0 ± 89.4
SecondaryPK: Time to Reach Maximum Plasma Drug Concentration (Tmax) of GZ/SAR402671

Tmax was defined as time to reach maximum plasma concentration of study drug.

Time frame:
Day 1 (predose and 1, 2, 4, 8, and 24 hours post-dose); Day 182 (predose and 1, 2, 4, 8, and 24 hours post-dose)
Reported as:
Median · hours
PK: Time to Reach Maximum Plasma Drug Concentration (Tmax) of GZ/SAR402671
hoursGZ/SAR402671
Day 18.00 (1.07 to 24.00)
Day 1824.00 (0.00 to 8.00)
SecondaryPK: Area Under Plasma Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24) of GZ/SAR402671

Area under the plasma concentration versus time curve of study drug from time 0 to 24 hours (AUC0-24) was calculated using the trapezoidal method over the dosing interval.

Time frame:
Day 1 (predose and 1, 2, 4, 8, and 24 hours post-dose); Day 182 (predose and 1, 2, 4, 8, and 24 hours post-dose)
Reported as:
Mean · ng*hour/mL
PK: Area Under Plasma Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24) of GZ/SAR402671
ng*hour/mLGZ/SAR402671
Day 1476 ± 125
Day 1824110 ± 2090
SecondaryPK: Terminal Half-life (t1/2z) of GZ/SAR402671

Plasma t1/2z was the time measured for the plasma concentration of drug to decrease by one half. The t1/2z was estimated based on 24-hour post-dose PK.

Time frame:
Day 1 (predose and 1, 2, 4, 8, and 24 hours post-dose); Day 182 (predose and 1, 2, 4, 8, and 24 hours post-dose)
Reported as:
Mean · hours
PK: Terminal Half-life (t1/2z) of GZ/SAR402671
hoursGZ/SAR402671
Day 186.8 ± 39.6
Day 182128.0 ± 59.0
SecondaryPK: Apparent Total Body Clearance of GZ/SAR402671 at Steady State (CLss/F)

Apparent total body clearance at steady state was a quantitative measure of rate of clearance of drug from the blood following oral administration, and is described in terms of volume of fluid clear of drug per time unit (eg, mL/min).

Time frame:
Predose and 1, 2, 4, 8, and 24 hours post-dose on Day 182
Reported as:
Mean · mL/hour
PK: Apparent Total Body Clearance of GZ/SAR402671 at Steady State (CLss/F)
mL/hourGZ/SAR402671
PK: Apparent Total Body Clearance of GZ/SAR402671 at Steady State (CLss/F)7490 ± 10900
SecondaryPK: Apparent Volume of Distribution of GZ/SAR402671 (Vss/F) at Steady State

Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of drug.

Time frame:
Predose and 1, 2, 4, 8, and 24 hours post-dose on Day 182

No measurements were reported for this outcome.

SecondaryPK: Cumulated Amount of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (Ae0-24)

Ae0-24 was the cumulated amount of study drug excreted in urine during the time interval of 0 to 24 hours.

Time frame:
0-24 hours on Day 182
Reported as:
Mean · mcg
PK: Cumulated Amount of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (Ae0-24)
mcgGZ/SAR402671
PK: Cumulated Amount of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (Ae0-24)3210.0 ± 1640.0
SecondaryPK: Percentage of Dose of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (fe0-24)

fe0-24 was the fraction of dose excreted in urine during the time interval of 0 to 24 hours.

Time frame:
0-24 hours on Day 182
Reported as:
Mean · percentage of dose
PK: Percentage of Dose of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (fe0-24)
percentage of doseGZ/SAR402671
PK: Percentage of Dose of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (fe0-24)21.4 ± 10.9
SecondaryPK: Renal Clearance (CLR) of GZ/SAR402671 From 0 to 24 Hours

CLR was calculated by dividing the cumulative amount of drug excreted in urine during the dosing interval of 0-24 hours by area under the plasma drug concentration time-curve during the dosing interval of 0-24 hours.

Time frame:
0-24 hours on Day 182
Reported as:
Mean · mL/hour
PK: Renal Clearance (CLR) of GZ/SAR402671 From 0 to 24 Hours
mL/hourGZ/SAR402671
PK: Renal Clearance (CLR) of GZ/SAR402671 From 0 to 24 Hours925 ± 407

Adverse events

Collected over Baseline up to 212 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GZ/SAR4026710/11 (0%)3/11 (27.3%)9/11 (81.8%)
Most frequent serious events
Most frequent serious events
EventGZ/SAR402671
HaemolysisBlood and lymphatic system disorders1/11
Floppy infantMusculoskeletal and connective tissue disorders1/11
Depressed moodPsychiatric disorders1/11
Most frequent other events
Showing 10 of 51
Most frequent other events
EventGZ/SAR402671
HeadacheNervous system disorders4/11
TinnitusEar and labyrinth disorders2/11
NauseaGastrointestinal disorders2/11
VomitingGastrointestinal disorders2/11
FatigueGeneral disorders2/11
Feeling hotGeneral disorders2/11
PyrexiaGeneral disorders2/11
RhinitisInfections and infestations2/11
Upper respiratory tract infectionInfections and infestations2/11
DizzinessNervous system disorders2/11

Baseline characteristics

Analysis was performed on full analysis set (FAS) that included all participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)GZ/SAR402671
Mean26.5 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)GZ/SAR402671
Female0
Male11
08

Study locations

8 sites
  • Investigational Site Number 840002
    Atlanta, Georgia 30322, United States
  • Investigational Site Number 840003
    Cincinnati, Ohio 45229, United States
  • Investigational Site Number 840001
    Fairfax, Virginia 22030, United States
  • Investigational Site Number 250001
    Garches, 92380, France
  • Investigational Site Number 616001
    Warszawa, 04-730, Poland
  • Investigational Site Number 643002
    Moscow, 125167, Russian Federation
  • Investigational Site Number 826003
    Birmingham, B15 2TH, United Kingdom
  • Investigational Site Number 826002
    Cambridge, CB2 OQQ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Sep 2016, 22 months.

Results were first posted in Dec 2019, 3 years 3 months after primary completion. A results delay was requested in Sep 2017.

Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2014
First posted
Aug 29, 2014
StartActual
Nov 2014
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results delay requested
Sep 5, 2017
Results first posted
Dec 17, 2019
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02228460
Responsible party
Sponsor
First posted
Aug 29, 2014
Start date
Nov 2014
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Dec 17, 2019
Last update
Dec 17, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venglustat

Start the discussion